OncoMatch/Clinical Trials/NCT06132711
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
Is NCT06132711 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for multiple myeloma.
This is a Single-center, open, single-arm clinical study, the goal of which was to evaluate the safety and efficacy of APRIL-BAFF-Bicephali CAR-T in relapsed and refractory multiple myeloma.The study consisted of four processes: patient enrollment screening; pre-CAR T cell therapy (including leukocyte apheresis, CAR T cell preparation and chemotherapy); inpatient monitoring phase for CAR T cell transfusion; and long-term follow-up phase
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Lab requirements
Liver function
ALT and AST <3 times normal; bilirubin <2.0mg / dl
Cardiac function
The patient has no serious heart, liver, kidney and other diseases
ALT and AST <3 times normal; bilirubin <2.0mg / dl; The patient has no serious heart, liver, kidney and other diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify